UCB Stock Other OTC
Stocks
UCBJF
BE0003739530
Pharmaceuticals
OTC Markets Traded| Market Cap | 43.7B 50.46B 40.74B 37.47B 70.73B 4,798B 71.52B 479B 188B 2,401B 190B 185B 7,950B | P/E 2026 * |
23.3x | P/E 2027 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise Value | 43.93B 50.72B 40.95B 37.66B 71.1B 4,823B 71.89B 481B 189B 2,413B 190B 186B 7,992B | EV / Sales 2026 * |
5.08x | EV / Sales 2027 * | 4.31x |
| Free-Float |
61.59% | Yield 2026 * |
0.64% | Yield 2027 * | 0.66% |
Last Transcript: UCB
| 1 day | -0.39% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 2020-06-30 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-12-31 | |
| Director/Board Member | 67 | 2014-12-31 | |
| Director/Board Member | 56 | 2014-04-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -.--% | - | - | 49.03B | |
| +1.04% | +10.52% | +34.86% | +0.28% | 75.96B | |
| +1.02% | +0.81% | -7.73% | +21.83% | 47.88B | |
| +0.54% | +2.73% | -51.25% | -49.87% | 43.39B | |
| -0.87% | -1.24% | +55.49% | -23.16% | 30.8B | |
| -0.66% | -5.74% | +54.13% | +88.28% | 24.45B | |
| -1.29% | +3.24% | +104.79% | -48.00% | 22.75B | |
| +0.61% | +3.01% | -7.45% | +212.39% | 19.24B | |
| -0.10% | -1.86% | +66.61% | +162.37% | 16.04B | |
| +1.05% | -6.85% | +60.29% | +118.00% | 15.87B | |
| Average | +0.09% | +0.03% | +34.42% | +53.57% | 32.93B | |
| Weighted average by Cap. | +0.25% | +2.42% | +24.81% | +26.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.65B 9.99B 8.06B 7.42B 14B 950B 14.16B 94.76B 37.19B 475B 37.51B 36.68B 1,574B | 9.7B 11.2B 9.04B 8.32B 15.7B 1,065B 15.87B 106B 41.7B 533B 42.06B 41.13B 1,765B |
| Net income | 1.87B 2.16B 1.75B 1.61B 3.03B 206B 3.06B 20.51B 8.05B 103B 8.12B 7.94B 341B | 2.34B 2.7B 2.18B 2.01B 3.79B 257B 3.83B 25.65B 10.07B 129B 10.16B 9.93B 426B |
| Net Debt | 228M 263M 213M 196M 369M 25.05B 373M 2.5B 981M 12.54B 990M 968M 41.52B | -1.94B -2.24B -1.81B -1.66B -3.14B -213B -3.18B -21.25B -8.34B -107B -8.41B -8.23B -353B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
